If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
15th Oct 20247:00 amRNSNotice of Results
15th Oct 20247:00 amRNSTransaction in Own Shares
10th Oct 202412:00 pmRNSPreliminary Q3 Results & Updated FY 2024 Guidance
8th Oct 20247:00 amRNSTransaction in Own Shares
3rd Oct 20242:30 pmRNSChair Succession Plan
1st Oct 20247:58 amRNSTotal Voting Rights
1st Oct 20247:00 amRNSTransaction in Own Shares
24th Sep 20247:00 amRNSTransaction in Own Shares
17th Sep 20247:00 amRNSTransaction in Own Shares
12th Sep 20247:00 amRNSHolding(s) in Company
10th Sep 20247:00 amRNSTransaction in Own Shares
4th Sep 20247:00 amRNSIndivior Provides Update on AEF0117
3rd Sep 20247:00 amRNSTransaction in Own Shares
2nd Sep 20249:00 amRNSTotal Voting Rights
27th Aug 20247:00 amRNSTransaction in Own Shares
20th Aug 20247:00 amRNSTransaction in Own Shares
20th Aug 20247:00 amRNSIndivior to Participate in Upcoming Events
14th Aug 20247:36 amRNSHolding(s) in Company
13th Aug 20247:00 amRNSTransaction in Own Shares
6th Aug 20247:00 amRNSCompletion of Share Repurchase Program
6th Aug 20247:00 amRNSTransaction in Own Shares
1st Aug 20248:24 amRNSTotal Voting Rights
30th Jul 20242:31 pmRNSBlock Listings of Shares
30th Jul 20242:18 pmRNSDirector/PDMR Shareholding
30th Jul 20242:16 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSTransaction in Own Shares
29th Jul 20242:40 pmRNSDirector/PDMR Shareholding
29th Jul 20242:36 pmRNSDirector/PDMR Shareholding
29th Jul 20242:17 pmRNSDirector/PDMR Shareholding
29th Jul 20242:15 pmRNSDirector/PDMR Shareholding
26th Jul 20243:37 pmRNSDirector/PDMR Shareholding
26th Jul 20243:34 pmRNSDirector/PDMR Shareholding
25th Jul 20247:10 amRNSShare Repurchase Program
25th Jul 20247:00 amRNSHalf-year Report
23rd Jul 20247:00 amRNSTransaction in Own Shares
18th Jul 20244:26 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSTransaction in Own Shares
15th Jul 20247:00 amRNSNotice of Results
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSHolding(s) in Company
9th Jul 20247:00 amRNSIndivior Provides Business Update
9th Jul 20247:00 amRNSTransaction in Own Shares
5th Jul 20243:39 pmRNSHolding(s) in Company
3rd Jul 20241:56 pmRNSHolding(s) in Company
1st Jul 20249:44 amRNSTotal Voting Rights
1st Jul 20247:00 amRNSTransaction in Own Shares
28th Jun 202410:54 amRNSHolding(s) in Company
28th Jun 202410:32 amRNSHolding(s) in Company
28th Jun 20247:00 amRNSTransaction in Own Shares
27th Jun 20248:06 amRNSTransition to U.S. Primary Listing Complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.